Cancer metastasis is multi-step process that requires cancer cells to jump through many hoops.The low-molecule-weight beparin (LMWH) has been reported effective for the treatment of metastasis to some extent, the mechanisms are proposed as anticoagulation, inhibition of heparanase, selectins, adhesion, angiogenesis mediated by the tumor cells, and the effects on cell cycle and apoptosis.

Objective To study CT diagnosis of vitreous diseases in childhood.Methods 95 patients with vitreous diseases from 1999-12—2004-10 were collected.The imaging features were analysed.Results Totally there were 5 cases of persistent hyperplastic primary vitreous,9 cases of premature with retinopathy,34 cases of retinoblastoma,3 cases of Coat’s disease,23 cases of nanophthalmus,16 cases of vitreous bleeding and 5 cases of endophalmitis.Conclusion Majority of vitreous diseases can be diagnosed definitely by CT,that can guide the clinical therapy.

Objective To study the technique and clincal value of biopsy during percutaneous vertebroplasty for the diagnosis of spine lesions.Methods From January 2003 to November 2005,94 patients that had been diagnosed with spinal tumors were admitted to our hospital.In these cases,totally 120 vertebrae were involved,including 3 cervical vertebrae,41 thoracic pieces,72 lumbar segments,and 4 vertebrae.Among the vertebrae,lyric lesions were found in 91,blastic in 9,and mixed in 20.Before operation,primary lesion of the spinal metastatic tumor had been confirmed in 76 patients (87 vertebrae).All the cases received percutaneous vertebroplasty,and biopsy was perfromed during the surgery.The positive rate of the pathological diagnosis was then analyzed.Results The percutaneous vertebroplasty and biopsy were completed in all the cases with a success rate of 100%.Of the 120 vertebrae,the primary diagnosis was confirmed in 114 (positive rate 95.0%),and the positive rate for metastasis cases were 93.1% (81/87).No injuries to the nerve and vessels were found in this series,no patient developeed hematoma or infection after the operation.A mean of 36.4-month follow-up was achieved in 80 patients (range,4 to 68 months),during this period,no tumor cells spreaded along needle tract or implanted into the skin.Conclusions Biopsy during percutaneous vertebroplasty can not only shorten treatment time and save medical cost,but also increase the safty of the surgical treatment as well as the aecruracy of pathological exmaination.

Objective To study clinical results of percutaneous vertebroplasty(PVP) for the treatment of symptomatic vertebral hemangiomas.Methods A total of 10 patients with vertebral hemangioma (thoracic vertebrae,6 patients;lumbar vertebrae,4 patients) were treated from December 2002 to April 2005.Under the guidance of digital subtraction angiography(DSA),a needle was advanced into the vertebral body via a unipedicular or bipedicular approach.The preparation of polymethylmethacrylate(PMMA) was mixed with 3 doses of powder,2 doses of liquid,and 1 dose of contrast until a doughy,cohesive consistency similar to toothpaste was obtained.Then the PMMA cement was injected into the vertebral body by using a high-pressure plunger.The total injection volume ranged 4~6 ml(mean,4.8 ml) in the thoracic vertebrae and 5~8 ml(mean,6.0 ml) in the lumbar vertebrae.Results The procedure was completed smoothly in all 10 patients.The operation time was 25~60 min(mean,39.5 min) and the intraoperative blood loss was 10~50 ml(mean,19.6 ml).No incidence of cement leakage or pulmonary embolism occurred.The 10 patients were followed for 2~30 months(mean,18 months).In 9 patients,free of signs and symptoms was achieved and no vertebral compression fracture or recurrence of hemangioma was observed.One patient with L_3 hemangioma still complained of mild and paroxysmal loin pain at 1 year after procedure,but the patient's normal activities were unaffected and no nervous dysfunction was found.Conclusions Percutaneous vertebroplasty is a safe and effective treatment for symptomatic vertebral hemangiomas.

Objective To study the effect of interleukin 13(IL-13)on mucin gene Muc5ac and EGFR expression in mouse lungs. Methods Twenty-four male BALB/c mice were randomly divided into control group and different dose of IL-13 (50ng, 100ng and 250ng) groups, six mice per group. Muc5ac mRNA, and Muc5ac and EGFR protein expressions were detected by RT-PCR and immunohistochemical method, respectively. Results Both Muc5ac and EGFR positive products were located in the cytoplasm of airway epithelial cells. Compared with control group, IL-13 could increase Muc5ac mRNA, and Muc5ac and EGFR protein expressions in dose-dependent manner(all P

Ca~(2+)-activated chloride channels (CaCC, CLCA) are a new family of chloride channels discovered recently, which are related to Ca~(2+)-sensitive chloride ions transport, and there were several members identified currently in different biologic bodies. New studies have shown that its member gob-5 in murine (its human counterpart is CaCC1) plays a pivotal role in airway goblet cell metaplasia, mucus overproduction, MUC5AC gene expression as well as airway hyperresponsiveness (AHR) in asthma, and is a key molecule in the induction of murine asthma and an asthma-related gene. Inhibition of their function and/or their signaling pathway may therefore provide a new therapeutic strategy for asthma.

The high incidence of postoperative recurrence of hepatocellular carcinoma ( HCC) is a most difficult obstacle for improving the prognosis of patients.Several adjuvant modalities have been developed to prevent recurrence in patients after surgery; nevertheless , there is no consensus regarding the standardized adjuvant therapy in terms of indications , clinical efficacy and interactions.In this article we review the currently available evidence in the medical literature on adjuvant therapy in HCC after radical resection.

Objective To assess the efficacy of postoperative adjuvant interferon (IFN) therapy on patients with hepatitis B virus (HBV) related hepatocellular carcinoma (HCC).Methods An electronic search for articles published from January 2000 to January 2013 was conducted to identify English language comparative studies evaluating IFN therapy on recurrence and survival after surgical treatment of HCC.Results A total of five trials consisting of 694 patients were included in the Meta-analysis.The estimated odds ratios (OR) for the 1-,2-,3-,and 5-year overall survival rates of HBV-related HCC were 3.37 (95％CI:1.18-6.27,P=0.000),2.36 (95％ CI:1.45-3.83,P=0.001),1.81 (95％ CI:1.21-2.72,P=0.004),and 1.93 (95％ CI:1.35-2.75,P=0.000),respectively.The OR for the 1-,2-,3-,and 5-year recurrence rates were 0.63 (95％ CI:0.44-0.91,P=0.014),0.84 (95％ CI:0.60-1.18,P=0.322),0.88 (95％ CI:0.63-1.22,P=0.431),and 0.78 (95％ CI:0.56-1.07,P=0.120),respectively.Conclusion This Meta-analysis shows that IFN therapy had a significant clinical effect in improving overall survival rates but not in decreasing recurrence rates of HBV infected HCC patients postoperatively.

6 cases(2 males to 4 females) who have received mandibula reconstruction with free vascularized fibular flaps in our hospital were studied retrospectively.The average length of the fibula grafts was 8.0 cm(range from 7.0 to 14 cm). 3 cases received primary insertion of osteointegrated dental implants into the free fibula flap. The mean follow-up of six cases of patients was 3 months to 1 year. The success rate was 100%. All patients spoke clearly. 4 patients could eat normally, the other two could eat soft food. 5/6 of patients with the recovery of facial appearance was satisfied. All patients were able to walk normally. No ankle unstability was reported. Vascularized free fibula flap is confirmed to be one of the optimal methods for mandible reconstruction by our study.

Fructose-1, 6-bisphosphatase (FBPase), a rate-limiting enzyme involved in the pathway of gluconeogenesis, can catalyze the hydrolysis of fructose-1, 6-bisphosphate to fructose-6-phosphate. Upon inhibiting the activity of FBPase, the production of endogenous glucose can be decreased and the level of blood glucose lowered. Therefore, inhibitors of FBPase are expected to be novel potential therapeutics for the treatment of type II diabetes. Recent research efforts were reviewed in the field of developing allosteric inhibitors interacting with the AMP binding site of FBPase.